Bio-Connect

Mouse IgG1 isotype control [15H6]

Research Use Only
GTX35014
GeneTex
ApplicationsFlow Cytometry, ImmunoFluorescence, Western Blot, ELISA, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, ImmunoHistoChemistry Paraffin, Neutralisation/Blocking, Other Application
Product group Antibodies
ReactivityHuman
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    Mouse IgG1 isotype control [15H6]
  • Delivery Days Customer
    10
  • Applications
    Flow Cytometry, ImmunoFluorescence, Western Blot, ELISA, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, ImmunoHistoChemistry Paraffin, Neutralisation/Blocking, Other Application
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    15H6
  • Concentration
    1 mg/ml
  • Host
    Mouse
  • Isotype
    IgG
  • Scientific Description
    Inclusion of an appropriate isotype control is essential for the proper interpretation of experimental results. Because isotype control antibodies have no relevant specificity, they enable the researcher to distinguish non-specific background binding from antigen-specific antibody binding. Non-specific binding of primary antibodies may occur due to either binding of antibody to Fc receptors or non-specific interactions with cellular proteins, lipids, or carbohydrates. Additionally, autofluorescence or endogenous enzyme activity in target cells may give a false positive that could be misinterpreted as antibody binding. These factors vary by target cell type and the isotype of the primary antibody. Therefore, the primary antibody used should be matched to an isotype control of identical species and isotype (including both heavy and light chains).
  • Reactivity
    Human
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352203

References

  • Biomimetic post-capillary venule expansions for leukocyte adhesion studies. Benson BL et al., 2018 Jun 19, Sci Rep
    Read more
  • Chemotherapeutic Agents Sensitize Resistant Cancer Cells to the DR5-Specific Variant DR5-B more Efficiently than to TRAIL by Modulating the Surface Expression of Death and Decoy Receptors. ?rtykov ?? et al., 2020 Apr 30, Cancers (Basel)
    Read more
  • Gain of function in the immune system caused by a ryanodine receptor 1 mutation. Vukcevic M et al., 2013 Aug 1, J Cell Sci
    Read more
  • Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile. Yagolovich AV et al., 2020 Apr, Transl Oncol
    Read more
  • Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile. Yagolovich AV et al., 2020 Apr, Transl Oncol
    Read more
  • Purpuric drug eruptions induced by EGFR tyrosine kinase inhibitors are associated with IQGAP1-mediated increase in vascular permeability. Sheen YS et al., 2020 Apr, J Pathol
    Read more
  • STAC3 variants cause a congenital myopathy with distinctive dysmorphic features and malignant hyperthermia susceptibility. Zaharieva IT et al., 2018 Dec, Hum Mutat
    Read more